文献速递乳腺癌

一线哌柏西利、瑞波西利或阿贝西利联合内分泌治疗在晚期HR阳性/HER2阴性乳腺癌患者中的真实世界有效性比较:多中心PALMARES-2研究结果

Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study.
PubMed 文献 · Ann Oncol · 2025-04-08

多中心观察性研究纳入18个意大利癌症中心2016年1月至2023年9月连续起始治疗的HR阳性/HER2阴性晚期乳腺癌患者1982例,比较一线哌柏西利、瑞波西利或阿贝西利联合内分泌治疗的真实世界无进展生存期。中位rwPFS为34.1个月,阿贝西利和瑞波西利较哌柏西利与更好rwPFS相关。

要点

  • 阿贝西利和瑞波西利较哌柏西利与更好rwPFS相关,aHR分别为0.76和0.83
  • 内分泌敏感人群中仅阿贝西利较哌柏西利与更好rwPFS相关
  • 仅骨病患者中三种CDK4/6i有效性相似

核心结论

  • 哌柏西利、瑞波西利和阿贝西利在HR阳性/HER2阴性晚期乳腺癌患者中具有不同的真实世界有效性。
  • 研究结果可支持临床医生在特定临床情境中选择最合适的CDK4/6i。

研究设计与样本

  • 多中心、观察性、基于人群的研究,比较一线哌柏西利、瑞波西利和阿贝西利联合内分泌治疗的有效性。
  • 纳入2016年1月至2023年9月在18个意大利癌症中心连续起始治疗的HR阳性/HER2阴性晚期乳腺癌患者。
  • 共纳入1982例患者,其中789例接受哌柏西利、736例接受瑞波西利、457例接受阿贝西利。
  • 主要终点为真实世界无进展生存期(rwPFS),采用多变量Cox回归模型校正临床相关变量。

主要发现

  • 中位rwPFS为34.1个月。
  • 在全研究队列中,阿贝西利和瑞波西利较哌柏西利与更好rwPFS相关:aHR 0.76(95%CI 0.63-0.92,P=0.004)和aHR 0.83(95%CI 0.73-0.95,P=0.007)。
  • 在内分泌敏感疾病患者中,仅阿贝西利较哌柏西利与更好rwPFS相关。
  • 在绝经前、内分泌耐药或luminal B样疾病患者中,阿贝西利和瑞波西利较哌柏西利更有效;在新发转移性疾病患者中,阿贝西利较瑞波西利和哌柏西利更有效;在ECOG体能状态较差患者中,阿贝西利较哌柏西利更有效。
  • 在仅骨病患者中,三种CDK4/6i有效性相似。

临床怎么用

  • 作者认为,研究结果可支持临床医生在特定临床情境中选择最合适的CDK4/6i。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) palbociclib, ribociclib and abemaciclib in combination with endocrine therapy (ET) are the standard-of-care, first-line treatment for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (HR-positive/HER2-negative aBC). However, no large head-to-head comparisons of the three CDK4/6is have been conducted so far. PATIENTS AND METHODS: We carried out a multicenter, observational, population-based study to compare the effectiveness of first-line palbociclib, ribociclib and abemaciclib in combination with ET in consecutive HR-positive/HER2-negative aBC patients who initiated the treatment between January 2016 and September 2023 in 18 Italian cancer centers. The primary endpoint of this analysis was real-world progression-free survival (rwPFS). Multivariable Cox regression models were used to adjust the association between individual CDK4/6i and rwPFS for clinically relevant variables. RESULTS: Of 1982 patients enrolled in the PALMARES-2 study, 789, 736 and 457 patients received palbociclib, ribociclib and abemaciclib, respectively. Median rwPFS was 34.1 months. In the whole study cohort, abemaciclib and ribociclib were associated with better rwPFS when compared with palbociclib [adjusted hazard ratio (aHR) 0.76, 95% confidence interval (CI) 0.63-0.92, P = 0.004 and aHR 0.83, 95% CI 0.73-0.95, P = 0.007, respectively]. In patients with endocrine-sensitive disease, only abemaciclib was associated with better rwPFS when compared with palbociclib. On the contrary, abemaciclib and ribociclib were more effective than palbociclib in patients who were premenopausal or had endocrine-resistant or luminal B-like disease, while abemaciclib was more effective than ribociclib and palbociclib in patients with de novo metastatic disease, and more effective than palbociclib in patients with poorer Eastern Cooperative Oncology Group performance status. The three CDK4/6i were similarly effective in patients who had bone-only disease. CONCLUSIONS: Palbociclib, ribociclib and abemaciclib have different real-world effectiveness in HR-positive/HER2-negative aBC patients. Our findings can support clinicians in choosing the most appropriate CDK4/6i in specific clinical contexts.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Provenzano L, Dieci MV, Curigliano G, et al. Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study. Ann Oncol. 2025. PMID: 40204155. doi:10.1016/j.annonc.2025.03.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。